190 related articles for article (PubMed ID: 26722235)
1. Improved survival associated with somatic
Lin DI
Oncol Lett; 2015 Nov; 10(5):2743-2748. PubMed ID: 26722235
[TBL] [Abstract][Full Text] [Related]
2. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
3. Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Fambrini M; Petraglia F; Pillozzi S; Noci I
Oncol Rep; 2019 Mar; 41(3):1560-1574. PubMed ID: 30569174
[TBL] [Abstract][Full Text] [Related]
4. The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a
Passarelli A; Ventriglia J; Pisano C; Cecere SC; Napoli MD; Rossetti S; Tambaro R; Tarotto L; Fiore F; Farolfi A; Bartoletti M; Pignata S
Front Oncol; 2022; 12():1088962. PubMed ID: 36713525
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.
Jiang Y; Malouf GG; Zhang J; Zheng X; Chen Y; Thompson EJ; Weinstein JN; Yuan Y; Spano JP; Broaddus R; Tannir NM; Khayat D; Lu KH; Su X
Oncotarget; 2015 Nov; 6(37):39865-76. PubMed ID: 26431491
[TBL] [Abstract][Full Text] [Related]
6. The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma.
Mozos A; Catasús L; D'Angelo E; Serrano E; Espinosa I; Ferrer I; Pons C; Prat J
Hum Pathol; 2014 May; 45(5):942-51. PubMed ID: 24746199
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
[TBL] [Abstract][Full Text] [Related]
8. TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma.
Travaglino A; Raffone A; Mollo A; Borrelli G; Alfano P; Zannoni GF; Insabato L; Zullo F
Arch Gynecol Obstet; 2020 May; 301(5):1117-1125. PubMed ID: 32253551
[TBL] [Abstract][Full Text] [Related]
9. Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
Espinosa I; D'Angelo E; Prat J
Gynecol Oncol; 2024 Apr; 186():94-103. PubMed ID: 38615479
[TBL] [Abstract][Full Text] [Related]
10. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
Marchiò C; De Filippo MR; Ng CK; Piscuoglio S; Soslow RA; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2015 May; 137(2):321-8. PubMed ID: 25701704
[TBL] [Abstract][Full Text] [Related]
11. The genetic landscape of endometrial clear cell carcinomas.
DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
[TBL] [Abstract][Full Text] [Related]
12. Exploring Morphologic and Molecular Aspects of Endometrial Cancer Under Progesterone Treatment in the Context of Fertility Preservation.
van Gent MD; Nicolae-Cristea AR; de Kroon CD; Osse EM; Kagie MJ; Trimbos JB; Hazelbag HM; Smit VT; Bosse T
Int J Gynecol Cancer; 2016 Mar; 26(3):483-90. PubMed ID: 26825822
[TBL] [Abstract][Full Text] [Related]
13. Why do some patients with stage 1A and 1B endometrial endometrioid carcinoma experience recurrence? A retrospective study in search of prognostic factors.
Ocak B; Sahin AB; Oz Atalay F; Ozsen M; Dakiki B; Ture S; Sali S; Tanriverdi O; Bayrak M; Ozan H; Demiroz Abakay C; Deligonul A; Cubukcu E; Evrensel T
Ginekol Pol; 2021 Jun; ():. PubMed ID: 34105738
[TBL] [Abstract][Full Text] [Related]
14. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
[TBL] [Abstract][Full Text] [Related]
17. Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Cohen SA; Turner EH; Beightol MB; Jacobson A; Gooley TA; Salipante SJ; Haraldsdottir S; Smith C; Scroggins S; Tait JF; Grady WM; Lin EH; Cohn DE; Goodfellow PJ; Arnold MW; de la Chapelle A; Pearlman R; Hampel H; Pritchard CC
Gastroenterology; 2016 Sep; 151(3):440-447.e1. PubMed ID: 27302833
[TBL] [Abstract][Full Text] [Related]
18. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
Mjos S; Werner HMJ; Birkeland E; Holst F; Berg A; Halle MK; Tangen IL; Kusonmano K; Mauland KK; Oyan AM; Kalland KH; Lewis AE; Mills GB; Krakstad C; Trovik J; Salvesen HB; Hoivik EA
Sci Rep; 2017 Aug; 7(1):10240. PubMed ID: 28860563
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
